ULTRAGENYX PHARMACEUTICAL INC. (RARE) Return on equity 2016–2024
ULTRAGENYX PHARMACEUTICAL INC. (RARE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-223.1%FY2024 · since FY2016: -51.9% → -223.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -223.1% | -2.4 pp |
| FY2023 | -220.7% | -19.8 pp |
| FY2022 | -201.0% | -151.8 pp |
| FY2021 | -49.2% | -33.1 pp |
| FY2020 | -16.2% | +45.4 pp |
| FY2019 | -61.6% | -29.1 pp |
| FY2018 | -32.5% | +46.3 pp |
| FY2017 | -78.8% | -26.9 pp |
| FY2016 | -51.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net incomeRARE Net marginRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating marginRARE Operating cash flowRARE Free cash flowRARE Capital expendituresRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Total liabilitiesRARE Shareholders’ equityRARE overview →